Pooled mesenchymal stem cells

The biomedical cell product (BMCP) contains a pooled culture of mesenchymal stem cells (MSC) obtained from adipose tissue or the olfactory lining of at least three donors.

This approach to obtaining BMCP from different donors allows:

– to achieve stable immuno-functional properties of a mixed culture,

– optimize and reduce the cost of the production process,

– to drastically reduce the time required for the production and accumulation of the therapeutically significant biomass of MSCs, which opens up the possibility for cell therapy of acute diseases.

Pooled cultures of allogeneic MSCs (poolMSCs) have more pronounced and stable immunomodulatory properties in comparison with MSCs obtained from a single donor. Due to the proven immunomodulatory, cytoprotective, and regenerative effects, as well as safety and good tolerability, pulMSCs have great clinical potential, especially in the treatment of autoimmune diseases. The low immunogenicity of poolMSCs makes it possible to use BMCPs based on them without selecting a donor-recipient pair.